GAMMA Investing LLC Grows Stock Holdings in Stryker Corporation $SYK

GAMMA Investing LLC grew its position in Stryker Corporation (NYSE:SYK) by 42.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,578 shares of the medical technology company’s stock after buying an additional 2,261 shares during the period. GAMMA Investing LLC’s holdings in Stryker were worth $2,386,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Varma Mutual Pension Insurance Co raised its holdings in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after purchasing an additional 5,100 shares during the last quarter. QRG Capital Management Inc. boosted its holdings in Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares during the last quarter. Swedbank AB grew its position in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after purchasing an additional 7,934 shares during the period. Crossmark Global Holdings Inc. raised its stake in shares of Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after buying an additional 6,367 shares during the last quarter. Finally, Cibc World Market Inc. lifted its holdings in shares of Stryker by 11.9% in the 4th quarter. Cibc World Market Inc. now owns 157,822 shares of the medical technology company’s stock valued at $55,470,000 after buying an additional 16,790 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $337.41 on Thursday. The stock has a market capitalization of $129.42 billion, a P/E ratio of 34.97, a PEG ratio of 2.14 and a beta of 0.76. The business has a 50 day simple moving average of $318.85 and a two-hundred day simple moving average of $334.29. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the company posted $3.13 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is owned by insiders.

Analysts Set New Price Targets

SYK has been the topic of a number of recent research reports. Argus set a $370.00 target price on Stryker in a research note on Thursday, July 9th. Piper Sandler decreased their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. BMO Capital Markets initiated coverage on shares of Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price for the company. Finally, Royal Bank Of Canada lowered their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.